Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation

Reuters

Jan 10

Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation

Orchestra Biomed Holdings Inc. has released a new corporate presentation highlighting its progress on pivotal-stage medical therapies targeting large, established markets. The company is advancing its AVIM Therapy, a programmable, pacemaker-delivered treatment for high blood pressure and hypertensive heart disease, and the Virtue SAB, a proprietary sirolimus balloon angioplasty system for atherosclerotic artery disease. The presentation notes ongoing pivotal trials, including the BACKBEAT and Virtue studies, and emphasizes the leadership team's extensive industry experience. Orchestra Biomed recently raised over $147 million in new capital, providing funding through key development milestones into late 2027. The company reports significant market opportunities, with annual global markets of over $17 billion for hypertensive heart disease and over $10 billion for atherosclerotic artery disease. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2602006304"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602006304\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602006304?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-10 06:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602006304","market":"fut","top_or_hot":-1,"title":"Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Orchestra Biomed Holdings Inc. has released a new corporate presentation highlighting its progress on pivotal-stage medical therapies targeting large, established markets. The company is advancing its AVIM Therapy, a programmable, pacemaker-delivered treatment for high blood pressure and hypertensive heart disease, and the Virtue SAB, a proprietary sirolimus balloon angioplasty system for atherosclerotic artery disease. The presentation notes ongoing pivotal trials, including the BACKBEAT and Virtue studies, and emphasizes the leadership team's extensive industry experience. Orchestra Biomed recently raised over $147 million in new capital, providing funding through key development milestones into late 2027. The company reports significant market opportunities, with annual global markets of over $17 billion for hypertensive heart disease and over $10 billion for atherosclerotic artery disease. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-10 06:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Orchestra Biomed Holdings Inc. has released a new corporate presentation highlighting its progress on pivotal-stage medical therapies targeting large, established markets. The company is advancing its AVIM Therapy, a programmable, pacemaker-delivered treatment for high blood pressure and hypertensive heart disease, and the Virtue SAB, a proprietary sirolimus balloon angioplasty system for atherosclerotic artery disease. The presentation notes ongoing pivotal trials, including the BACKBEAT and Virtue studies, and emphasizes the leadership team's extensive industry experience. Orchestra Biomed recently raised over $147 million in new capital, providing funding through key development milestones into late 2027. The company reports significant market opportunities, with annual global markets of over $17 billion for hypertensive heart disease and over $10 billion for atherosclerotic artery disease. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OBIO","symbol_name":"Orchestra BioMed","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL6xhzl5:1","article_id":"2602006304","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602006304","pubTimestamp":1767998167,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Orchestra Biomed Holdings Inc. has released a new corporate presentation highlighting its progress on pivotal-stage medical therapies targeting large, established markets. The company is advancing its AVIM Therapy, a programmable, pacemaker-delivered treatment for high blood pressure and hypertensive heart disease, and the Virtue SAB, a proprietary sirolimus balloon angioplasty system for atherosclerotic artery disease. The presentation notes ongoing pivotal trials, including the BACKBEAT and Virtue studies, and emphasizes the leadership team's extensive industry experience. Orchestra Biomed recently raised over $147 million in new capital, providing funding through key development milestones into late 2027. The company reports significant market opportunities, with annual global markets of over $17 billion for hypertensive heart disease and over $10 billion for atherosclerotic artery disease. You can access the full presentation through the link below.Disclaimer: This news brief was c","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OBIO":"Orchestra BioMed","BK4082":"医疗保健设备"},"translate_title":"Orchestra Biomed在新的公司演示中强调了关键的高血压和动脉疾病疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OBIO":0.9},"content_text":"Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation\n    \n\n        Orchestra Biomed Holdings Inc. has released a new corporate presentation highlighting its progress on pivotal-stage medical therapies targeting large, established markets. The company is advancing its AVIM Therapy, a programmable, pacemaker-delivered treatment for high blood pressure and hypertensive heart disease, and the Virtue SAB, a proprietary sirolimus balloon angioplasty system for atherosclerotic artery disease. The presentation notes ongoing pivotal trials, including the BACKBEAT and Virtue studies, and emphasizes the leadership team's extensive industry experience. Orchestra Biomed recently raised over $147 million in new capital, providing funding through key development milestones into late 2027. The company reports significant market opportunities, with annual global markets of over $17 billion for hypertensive heart disease and over $10 billion for atherosclerotic artery disease. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orchestra Biomed Holdings Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}